Breast Cancer Clinical Trials

A listing of Breast Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 74 clinical trials
UPCC 03120: Randomized Double-Blind Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)

TBD

  • 0 views
  • 19 Feb, 2024
  • 1 location
Cancer detection rate of Abbreviated (Fast) Breast MRI (AB-MR) after negative Digitial Breast Tomosynthesis in Women status post Conservation Therapy (BCT)

Women treated for primary breast cancer who undergo breast conservation therapy face an increased risk of developing a second breast cancer in the ipsilateral and the contralateral breast.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF NIRAPARIB AND TUMOR-TREATING FIELDS IN RECURRENT GLIOBLASTOMA

PARP inhibitors have revolutionized the care of ovarian and breast cancers with BRCA mutations, and, in the case of niraparib, the care of women with ovarian cancer regardless of BRCA status. Based on recent advances in cancer genetics, it is now understood that cellular defects in homologous recombination repair in …

  • 0 views
  • 19 Feb, 2024
  • 1 location
FES PET/CT in Endocrine Refractory Breast Cancer

  Patients may undergo primary tumor or metastatic biopsy, as part of their clinical care.  Patients may also be enrolled in a separate breast cancer biopsy protocol entitled “Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer” (METAMORPH).  We will ask permission to access tissue collected as part of clinical …

  • 0 views
  • 19 Feb, 2024
  • 2 locations
UPCC 24116: A Phase II Pilot Trial of Hydroxychloroquine Everolimus or the Combination for Prevention of Recurrent Breast Cancer

The main purpose of this study is to: 1) determine the feasibility of giving hydroxychloroquine, everolimus or the combination to people with disseminated tumor cells detected in their bone marrow. 2) determine how tolerable these drugs are in people who have completed treatment for breast cancer. 3) determine how well …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 1/2 Study of Oral LOXO-292 in Patients

LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …

  • 0 views
  • 19 Feb, 2024
  • 1 location
IMAGING OF IN VIVO SIGMA-2 RECEPTOR EXPRESSION WITH [18F]ISO-1 POSITRON EMISSION TOMOGRAPHY (PET/CT) IN METASTATIC BREAST CANCER

   Results of the standard breast cancer pathology immunohistochemistry (IHC) panel (usually estrogen receptor (ER), progesterone receptor (PgR) and HER2/neu) will be collected from the medical record for both metastatic breast cancer biopsy and primary breast cancer biopsy or surgery, when available.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase I/II trial of olaparib palbociclib and fulvestrant in patients with BRCA mutation-associated hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer

The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) breast cancer and BRCA1 or BRCA2 mutations.

  • 0 views
  • 19 Feb, 2024
  • 1 location
PALLAS: PALbociclib CoLlaborative Adjuvant Study

The purpose of this study is to compare any good and bad effects of using 2 years of the investigational drug Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone and to evaluate the likelihood that invasive breast cancer returns.

  • 0 views
  • 19 Feb, 2024
  • 1 location
METAMORPH

This is a cohort study of women with suspected or confirmed recurrent breast cancer, with accessible tumor by standard clinical biopsy, prior to starting a new therapy for recurrent metastatic disease. Study participants will be ascertained from the population of all persons greater than eighteen years of age receiving care …

  • 0 views
  • 19 Feb, 2024
  • 1 location